8i2n
From Proteopedia
The RIPK1 kinase domain in complex with QY7-2B compound
Structural highlights
FunctionRIPK1_HUMAN Serine-threonine kinase which transduces inflammatory and cell-death signals (programmed necrosis) following death receptors ligation, activation of pathogen recognition receptors (PRRs), and DNA damage. Upon activation of TNFR1 by the TNF-alpha family cytokines, TRADD and TRAF2 are recruited to the receptor. Ubiquitination by TRAF2 via 'Lys-63'-link chains acts as a critical enhancer of communication with downstream signal transducers in the mitogen-activated protein kinase pathway and the NF-kappa-B pathway, which in turn mediate downstream events including the activation of genes encoding inflammatory molecules. Polyubiquitinated protein binds to IKBKG/NEMO, the regulatory subunit of the IKK complex, a critical event for NF-kappa-B activation. Interaction with other cellular RHIM-containing adapters initiates gene activation and cell death. RIPK1 and RIPK3 association, in particular, forms a necrosis-inducing complex.[1] [2] [3] Publication Abstract from PubMedReceptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a key regulator in inflammation and cell death and is involved in mediating a variety of inflammatory or degenerative diseases. A number of allosteric RIPK1 inhibitors (RIPK1i) have been developed, and some of them have already advanced into clinical evaluation. Recently, selective RIPK1i that interact with both the allosteric pocket and the ATP-binding site of RIPK1 have started to emerge. Here, we report the rational development of a new series of type-II RIPK1i based on the rediscovery of a reported but mechanistically atypical RIPK3i. We also describe the structure-guided lead optimization of a potent, selective, and orally bioavailable RIPK1i, 62, which exhibits extraordinary efficacies in mouse models of acute or chronic inflammatory diseases. Collectively, 62 provides a useful tool for evaluating RIPK1 in animal disease models and a promising lead for further drug development. Structure-based development of potent and selective type-II kinase inhibitors of RIPK1.,Qin Y, Li D, Qi C, Xiang H, Meng H, Liu J, Zhou S, Gong X, Li Y, Xu G, Zu R, Xie H, Xu Y, Xu G, Zhang Z, Chen S, Pan L, Li Y, Tan L Acta Pharm Sin B. 2024 Jan;14(1):319-334. doi: 10.1016/j.apsb.2023.10.021. Epub , 2023 Nov 8. PMID:38261830[4] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
Categories: Homo sapiens | Large Structures | Gong XY | Li Y | Meng HY | Pan LF